جست‌وجوی استاد و پژوهشگر

• Organic Chemistry
• Organic Synthesis
• Medicinal Chemistry

Radomir N. Saičić is a Full Professor at the Department of Organic Chemistry, Faculty of Chemistry, University of Belgrade. He has been a faculty member since 1984, progressing through academic ranks to become a full professor in 2002. He currently serves as Head of the Department of Organic Chemistry (since October 2023) and Chairman of the Ethical Committee (since July 2021). Dr. Saičić received his academic training at the University of Belgrade: 1979-1983: Undergraduate studies in Chemical Sciences at Faculty of Natural Sciences and Mathematics 1983-1987: Master's degree in Chemical Sciences 1988-1991: Doctorate in Chemical Sciences at Faculty of Chemistry 1995-1996: Postdoctoral studies at Institute of Natural Products Chemistry, CNRS (France) His research focuses on developing novel synthetic methodologies and applying them to the total synthesis of complex natural products and biologically active compounds. His group has pioneered work in radical annulations, remote functionalization reactions, organocatalyzed Tsuji-Trost reactions, and synthetic equivalents for challenging enolates. Their research has successfully produced synthetic routes to important compounds including 7-deoxytaxol, cytoxazone, periplanone C, abyssomicin C, and oseltamivir phosphate (Tamiflu). Dr. Saičić's publication record demonstrates consistent contributions to organic synthesis methodology and natural product chemistry, with recent work emphasizing stereoselective transformations and applications to biologically relevant targets. His research shows increasing focus on medicinal applications of synthetic chemistry, particularly in developing new anticancer and antiviral agents. His scientific achievements have been recognized with several prestigious awards: 1987: October prize of the City of Belgrade for students (best MS thesis) 1995: Medal of the Serbian Chemical Society for scientific excellence 2007: Award of the City of Belgrade for best scientific achievement As a principal investigator, Dr. Saičić has led numerous research projects, currently directing two major initiatives: 'Small Molecule Anti-RNA-virus Therapy' (SMART Repurposing) targeting COVID-19 treatments and 'New Synthetic Methods and their Applications' (New SMART Synthesis) for complex molecule construction. His previous projects have focused on taxol analogs, antitumor agents, and vasodilator development. He leads an active research group comprising scientific advisors, associate professors, assistant professors, research associates, and graduate students working across laboratories 416, 427, and 470 at the Faculty of Chemistry. His mentorship has contributed significantly to the development of organic chemists in Serbia and beyond.

David Garciaمشاهده پروفایل

استادیار

• Molecular Biology
• Genetics
• Cell Biology
• +۵ مورد دیگر

David Garcia is an Assistant Professor in the Department of Biology at the University of Oregon, affiliated with the College of Arts and Sciences. His research focuses on epigenetic mechanisms, particularly prion-based inheritance and RNA modifications in yeast systems. Research Interests: The Garcia Lab investigates how epigenetic traits enable rapid phenotypic adaptation to environmental stress. Key areas include prion-forming RNA-modifying enzymes, stress response dynamics, and RNA chemical modification profiling using direct RNA-sequencing technologies. Research Trends: His work spans molecular characterization of prions (2014-2021), bacterial metabolite interactions with prion systems (2016), and RNA-RNA pairing mechanisms (2011-2012), with implications for human health and disease. Contact: Email: dmgarcia@uoregon.edu | Office: 312 Streisinger Hall, University of Oregon

Julian Charles Raynerمشاهده پروفایل

استاد

• Malaria Research
• Plasmodium Parasitology
• Cell Biology
• +۵ مورد دیگر

Professor Julian Charles Rayner is a distinguished malaria researcher and Professor of Cell Biology at the University of Cambridge, where he serves as Director of the Cambridge Institute for Medical Research (CIMR) within the School of Clinical Medicine. His research focuses on understanding the molecular mechanisms of malaria infection, particularly how Plasmodium parasites invade human red blood cells. Rayner's laboratory investigates both the proteins involved in erythrocyte invasion (potential vaccine targets) and the genetic makeup of parasites (potential drug targets). Rayner's research interests span multiple areas of malaria biology, including the origins of Plasmodium falciparum (which he helped demonstrate likely originated in gorillas rather than chimpanzees), the molecular mechanisms of erythrocyte invasion, parasite genetics and evolution, and host-pathogen interactions. His work combines advanced genomic, proteomic, and cell biological approaches to identify vulnerabilities in the malaria parasite that could be targeted by new interventions. Analysis of Rayner's recent publications reveals a strong focus on parasite genetics and invasion mechanisms. His team has made significant contributions to understanding how genetic variation in both the parasite and human host influences malaria infection outcomes. Notable research directions include the characterization of invasion ligands (particularly PfEBA and PfRH families), the development of genomic resources like the Pf7 and Pf8 datasets, and investigations into human genetic factors that confer resistance to malaria such as the Dantu blood group variant. CA Wright Memorial Medal (British Society for Parasitology, 2015) Fellow of EMBO (European Molecular Biology Organization, 2022) Fellowship of the Academy of Medical Sciences (UK, 2023) FMedSci designation Rayner leads a dynamic research group comprising multiple postdoctoral researchers, PhD students, and technical staff. His laboratory receives substantial funding from major organizations including the Wellcome Trust, National Institutes of Health (US), and European Union. Beyond his research program, Rayner has been actively involved in science communication, notably creating the 'Malaria Challenge' interactive game to educate school children about malaria. His leadership extends to directing the Cambridge Institute for Medical Research and previously serving as Director of Connecting Science for the Wellcome Genome Campus.

• Machine Learning
• Computer Vision
• Data Compression
• +۳ مورد دیگر

Don Adjeroh is a Professor and Associate Chair in the Lane Department of Computer Science and Electrical Engineering at West Virginia University (WVU). He serves as Graduate Coordinator for CS programs and has led multiple NSF-sponsored projects including Bridges in Digital Health and Multi-Scale Integrative Approach to Digital Health . His research focuses span Machine Learning , Bioinformatics , Computational Biology , and Data Compression . NSF CAREER Award recipient Collaborated with institutions like University of Central Florida and University of Canterbury Led workshops on Plant Image Analysis and Long Non-Coding RNA research His academic contributions include co-authoring the book The Burrows Wheeler Transform: Data Compression, Suffix Arrays, and Pattern Matching (Springer, 2008) and developing software tools like BSMP and PSA for data compression and protein family modeling. He teaches graduate-level courses in String Algorithms and Information Theory , with former projects involving undergraduate and graduate students in DNA microarray image processing and 3D video compression research. Key Scientific Awards : NSF CAREER Award NASA-WV Space Consortium funding WV-EPSCOR grants NSF-CITeR support DOD-ONR/DHS/DOJ/NIJ/NHPRC sponsorships

• Leukemia Biology
• Leukemia Therapeutics
• Acute Myeloid Leukemia
• +۵ مورد دیگر

Dr. David Claxton is a Professor in the Department of Medicine, Division of Hematology and Oncology at Penn State College of Medicine. He is affiliated with the Penn State Cancer Institute, where he leads research initiatives in the Next-Generation Therapies program. His work focuses on advancing cancer treatment through innovative research approaches and clinical applications. Dr. Claxton's research interests span multiple areas of leukemia biology and treatment: Leukemia biology and therapeutics Leukemia molecular genetics and diagnostics Acute myeloid leukemia and related disorders Drug development and clinical studies Blood and marrow transplantation Clinical supportive care His recent publications demonstrate a strong focus on precision medicine approaches to leukemia treatment, with particular emphasis on molecular subtyping, novel therapeutic targets, and improved transplantation techniques. The research shows a trend toward increasingly sophisticated molecular characterization of leukemias and development of targeted therapies based on these findings. Dr. Claxton has received recognition for his collaborative research efforts, most notably the Outstanding Collaborative Research Team award in 2015. As an active researcher, Dr. Claxton serves as Principal Investigator on multiple significant research projects, including the Tissue Repository and Animal Models Core (funded by the National Cancer Institute, 2020-2025) and Targeted Sphingolipid Metabolism for Treatment of AML (2013-2025). His laboratory maintains a valuable resource of cryopreserved human leukemia and lymphoma samples that are used in research and available to collaborators. Dr. Claxton's laboratory operates the Tissue Repository, which has banked numerous samples of human leukemias and lymphomas. These viably cryopreserved specimens support ongoing research into cancer biology and therapeutic development, serving as a critical resource for his team and collaborators.

Rani Georgeمشاهده پروفایل

دانشیار

• Pediatric Oncology
• Cancer Biology
• Molecular Target Identification
• +۳ مورد دیگر

Rani George is an Associate Professor of Pediatrics at Harvard Medical School and an Attending Physician at Dana-Farber/Boston Children's Cancer and Blood Disorders Center . Her research integrates basic developmental biology , cancer biology , and clinical trial design to target molecular aberrations in pediatric solid tumors. Medical School: A.M. Dogliotti College of Medicine, University of Liberia PhD: University of Newcastle-upon-Tyne, UK Clinical Training: Royal Victoria Infirmary (Pediatrics), Boston Children's Hospital (Hematology-Oncology) Her laboratory focuses on neuroblastoma , a pediatric solid tumor, with three core research axes: (1) Molecular target identification in neuroblastoma cells, particularly ALK mutations and MYCN oncogene ; (2) Sympathetic nervous system development with emphasis on PHOX2B transcription factor ; and (3) Mechanisms of therapy resistance in relapsed neuroblastoma. The program combines preclinical drug development with clinical trials for treatment-resistant cases. Recent publications demonstrate her group's leadership in neuroblastoma research , spanning RNA methylation (METTL3/METTL14), microRNA therapy (miR-124), AI-driven tumor classification , and ALK inhibitor development . Her work frequently appears in high-impact journals like Nature , Cancer Cell , and National Cancer Institute journals . Research funding comes from prestigious sources including the National Institutes of Health , Sidney Kimmel Foundation , and American Cancer Society . Her laboratory develops translational programs that bridge basic science discoveries with clinical applications through collaborations with Dana-Farber and Boston Children's Hospital resources.

Jan Lammerdingمشاهده پروفایل

استاد

• Cell nucleus mechanobiology
• Mechanotransduction
• Cancer cell migration and metastasis
• +۵ مورد دیگر

Jan Lammerding is a Professor at Cornell University's Meinig School of Biomedical Engineering and the Weill Institute for Cell and Molecular Biology. His research focuses on nuclear mechanobiology, investigating how mechanical forces affect nuclear structure and function in cancer metastasis and muscular dystrophies. He has developed microfluidic platforms to study nuclear deformation and holds fellowships from BMES, AIMBE, and ASCB. Education: Diplom Ingenieur (RWTH Aachen), B.E. (Dartmouth), Ph.D. (MIT) Leadership: Director of Graduate Studies (2011-2024), Associate Director of Meinig School (2024-) Research spans nuclear envelope rupture in cancer cells, mechanotransduction pathways, and Ledercq Foundation-funded projects on laminopathies. His lab has produced 15+ articles (2023-2025) covering topics like microtubule-induced nuclear damage , 3D hydrogel migration , and mechanical stress epigenetic effects . Awards include Keith Porter Medal , NSF CAREER , and Cornell Teaching Excellence honors.

Eva L. Feldmanمشاهده پروفایل

استاد

• Neurodegenerative Diseases
• Diabetic Neuropathy
• Amyotrophic Lateral Sclerosis (ALS)
• +۳ مورد دیگر

Eva L. Feldman is a Professor of Neurology at the University of Michigan's Michigan Medicine school and holds the James W. Albers Distinguished University Professor and Russell N. DeJong Professor titles. She directs the ALS Center of Excellence , Program for Neurology Research & Discovery , and NeuroNetwork for Emerging Therapies , focusing on translating lab findings into clinical applications for neurological diseases. Academic Rank: Professor of Neurology Leadership: Director of three major research initiatives Research Scope: ALS, Alzheimer's, diabetic neuropathy, and environmental neurotoxicology Her research integrates RNA biology (mRNA stability, microRNA dysregulation, RNA exosomes) with metabolic and epigenetic mechanisms to identify early biomarkers and therapeutic targets. Current projects include exploring the cGAS/STING pathway in metabolic stress-induced cognitive decline and the impact of cyanobacterial toxins on ALS progression, reflecting her dual focus on molecular pathogenesis and public health implications. The 2025 article trends highlight her work at the intersection of neurodegeneration , metabolic disorders , and environmental factors . Her team uses single-cell transcriptomics , multi-omics , and epidemiological modeling to unravel disease mechanisms across ALS, Alzheimer's, diabetes, and obesity-related neuropathies. Scientific Recognition: Continuously NIH-funded since 1989 Best Doctors in America listing Member of the National Academy of Medicine Fellow of the American Association for the Advancement of Science Award for Excellence from the American Neurological Association Collaborative Expertise: Her lab fosters interdisciplinary partnerships with genetics, physiology, bioinformatics, and environmental science experts. She mentors students through hands-on research in high-impact projects and advocates for expanding ALS clinical research networks. Labs & Teams: Leads the Program for Neurology Research & Discovery and NeuroNetwork for Emerging Therapies , which leverage advanced technologies for neurotherapeutic innovation. The ALS Center of Excellence under her direction drives Michigan’s mandatory ALS case reporting initiative to enhance disease surveillance.

Benedikt Kesslerمشاهده پروفایل

استاد

• Ubiquitin-Proteasome System
• Deubiquitylating Enzymes
• Proteomics
• +۷ مورد دیگر

Professor Benedikt Kessler is a Full Professor of Biochemistry and Mass Spectrometry at the Target Discovery Institute within the Nuffield Department of Medicine at the University of Oxford. He leads a research group focused on the ubiquitin-proteasome system and deubiquitylating enzymes, with significant contributions to cancer research and neurodegenerative disease therapeutics. Professor Kessler received his B.A. in Biochemistry from the Swiss Federal Institute of Technology in 1992, followed by a Ph.D. in Immunology from the Ludwig Institute for Cancer Research. He completed post-doctoral training at Harvard Medical School under Hidde Ploegh before joining the University of Oxford in 2004 as a Research Group Leader. He established his independent research group in 2005 and relocated to the Target Discovery Institute in 2013. In 2014, he was promoted to Full Professor of Biochemistry & Life Science Mass Spectrometry. His research focuses on deubiquitylating enzymes (DUBs) and their role in cellular processes, with particular emphasis on cancer development and neurodegenerative disorders. Professor Kessler pioneered chemoproteomics methods to profile active ubiquitin processing enzymes and has made significant contributions to understanding how ubiquitin-based pathways can be targeted therapeutically. His laboratory developed ubiquitin-based active site directed probes that enabled profiling of active cellular DUB content, leading to discoveries about OTUB1 in infection and prostate cancer, USP4 and USP47 in DNA repair, and USP18 in immuno-oncology. His work has directly contributed to the development of novel inhibitors for DUBs including USP30 (for Parkinson's disease), USP28 (for squamous lung carcinoma), and USP7 (for multiple myeloma). Analysis of Professor Kessler's recent publications (2024-2025) reveals an expanding research portfolio with significant contributions across multiple domains: neurodegenerative disease therapeutics through hydrogen deuterium exchange mass spectrometry, kidney transplant immunology, ubiquitin pathway characterization in infectious diseases like malaria, and novel DUB inhibitor development. His work consistently bridges fundamental biochemistry with clinical applications, particularly in cancer therapeutics and neurodegenerative disorders, while increasingly incorporating advanced machine learning approaches for biomarker discovery. Scientific Awards and Recognition Cesar Roux Research Award of the Faculty of Medicine, Lausanne University Human Frontier Science Program Organization long-term fellowship Roche Research Foundation post-doctoral fellowship Multiple Myeloma Research Foundation Senior Research Award Wellcome Trust VIP Award (2005) MRC New Investigator Award (2006-2009) Professor Kessler's research has received substantial funding throughout his career, including the MRC New Investigator Award that supported his early independent work at Oxford. His contributions to understanding the ubiquitin-proteasome system led to translational applications, most notably contributing to the development of Velcade™ for multiple myeloma treatment. He is an active member of several prestigious scientific organizations including the British Mass Spectrometry Society, British Society of Cell Biology, and the American Association for Cancer Research. Professor Kessler serves as a NIH study section member and collaborates extensively through the DUB Alliance and Pfizer's Innovative Technology Enabling Network (ITEN). Professor Kessler leads the TDI Mass Spectrometry Laboratory at the Nuffield Department of Medicine, where his team develops advanced chemoproteomics methods to profile active ubiquitin processing enzymes. His laboratory maintains extensive collaborations across Oxford University including with the Oxford Ludwig Institute, Jenner Institute, Weatherall Institute of Molecular Medicine, and Structural Genomics Consortium. Internationally, he collaborates with researchers at Leiden University and maintains connections with the Harvard Medical School community where he began his academic career.

Timothy D. Dyeمشاهده پروفایل

استاد

• Applied Public Health
• Social Determinants of Health
• Global Health
• +۷ مورد دیگر

Timothy D. Dye is a Professor at the University of Rochester School of Medicine and Dentistry with joint appointments in the Department of Obstetrics and Gynecology and Department of Health Humanities and Bioethics. As a medical anthropologist and social epidemiologist, he leads an extensive research program focused on applied public health in global and marginalized communities. Education includes: J.D. from Syracuse University College of Law (2024) M.A. in Documentary Film and History from Syracuse University (2013) Ph.D. in Anthropology from University at Buffalo (1993) M.S. in Epidemiology from University at Buffalo (1990) M.P.A. and M.A. in International Relations from Syracuse University (1987) B.A. in International Relations from Syracuse University (1985) His research integrates qualitative, quantitative, and community-based approaches to address health priorities through ecological frameworks. Primary focus areas include: 1) Global health systems in Latin America/Caribbean and Deaf communities, 2) Social determinants of perinatal outcomes, 3) Health technology for community action, and 4) Ethical community-researcher partnerships emphasizing co-creation of knowledge. Recent publications demonstrate strong thematic focus on health equity, community engagement methodologies, and innovative applications of technology in public health. Work consistently addresses structural barriers in healthcare systems while developing culturally responsive interventions. Publication trends reveal extensive work in maternal/child health, health disparities research, and global health implementation science. Significant scientific recognition includes: University of Rochester Faculty Diversity Award Two Fulbright Specialist awards Elected Fellow of four prestigious scholarly societies Antarctic Service Medal MEDICC Scholar recognition Directs the Dye Lab, which manages multiple NIH/CDC-funded global health initiatives including maternal health technology projects in Latin America (MundoComm), HIV rapid treatment programs (NY State AIDS Institute), and deaf health research. The lab emphasizes community-driven research with partners in over 30 countries. Current grants explore genetic research participation barriers, health impacts of language deprivation, and legal frameworks for biospecimen research. Leads interdisciplinary teams across the Global Network, Diálogo Social Científico, and Translational Biomedical Science PhD program. The lab operates through collaborative partnerships with communities, prioritizing local knowledge and self-determination in research design.

• Structural biology
• Cryo-EM
• G protein-coupled receptors (GPCRs)
• +۴ مورد دیگر

Jonathan F. Fay is an Assistant Professor in the Department of Biochemistry and Molecular Biology at the University of Maryland School of Medicine. His research focuses on structural biology, particularly using cryo-EM to study G protein-coupled receptors (GPCRs), membrane proteins, and ABC proteins. He also develops methods to improve cryo-EM data collection and analysis. Education: B.A. in Biochemistry/Molecular Biology, Reed College (1995–1999) Ph.D. in Biochemistry/Molecular Biology, Oregon Health & Science University (2006–2012) His lab specializes in structural studies of GPCRs, including their pharmacological and functional mechanisms, and explores techniques to enhance cryo-EM resolution and efficiency. Key areas include allosteric regulation, RNA editing in receptors, and protein dynamics. The 2022 publications highlight work on serotonin receptors, cryo-EM optimization, and LSD-induced signaling. Earlier work (2018, 2015) investigated CFTR channel structure and cannabinoid receptor dynamics. Topics span structural biology, neuroscience, and pharmacology. Research keywords include membrane proteins, cryo-EM, and structural biology. His work bridges molecular mechanisms with broader implications in neuropharmacology and disease-related protein functions. Labs: Focus on cryo-EM and structural studies of GPCRs, ABC proteins, and method development

• Molecular Dermatology
• Genodermatoses
• Gene Therapy
• +۴ مورد دیگر

Stefan Hainzl serves as a Research Associate at Paracelsus Medical University Salzburg, holding dual appointments in the Research Program for Molecular Therapy in Genodermatoses and the University Clinic for Dermatology and Allergology. With 82 publications spanning from 2010 to 2025, his research program demonstrates sustained productivity in molecular dermatology. Dr. Hainzl's research focuses on genetic skin disorders, particularly epidermolysis bullosa and related genodermatoses. His work spans multiple approaches including CRISPR-Cas gene editing , antisense oligonucleotide therapy , and molecular diagnostics . The research fingerprint shows strong concentration in revertant mosaicism (100%), epithelial-mesenchymal transition (100%), squamous cell biology (100%), and antisense applications (100%), with additional focus on oligonucleotide therapeutics and squamous cell carcinoma. Analysis of his recent publications reveals a clear trajectory toward developing molecular therapies for inherited skin disorders, with increasing emphasis on gene editing technologies. His 2024-2025 work shows particular focus on CRISPR applications for keratin disorders and splicing modulation approaches for recessive dystrophic epidermolysis bullosa. His scientific contributions include: Development of fluorescence-based screening for gene editing molecules Investigation of HMCN1 variants in epidermolysis bullosa CRISPR-Cas applications for keratin disorders Antisense oligonucleotide approaches for splicing modulation Dr. Hainzl frequently collaborates with senior researchers including Koller, Kocher, and Bauer, often contributing as co-author though occasionally serving as first author on significant therapeutic development papers. His work has gained attention across multiple platforms with mentions on social media, news outlets, and academic networks.

Mary Lauren Bentonمشاهده پروفایل

استادیار

• Computational Biology
• Gene Regulation
• Biomedical Informatics
• +۳ مورد دیگر

Dr. Mary Lauren Benton is an Assistant Professor in the Department of Computer Science at Baylor University's College of Engineering and Computer Science. She holds a Ph.D. and M.S. in Biomedical Informatics from Vanderbilt University (2020, 2018) and a B.S.I. in Bioinformatics from Baylor University (2015). Education: Ph.D. (Vanderbilt, 2020), M.S. (Vanderbilt, 2018), B.S.I. (Baylor, 2015) Her research focuses on computational biology and gene regulation, particularly how DNA sequences influence genome function and human disease risk through integrated datasets. Recent work explores enhancer-gene interactions, epigenetic mechanisms, and the application of graph neural networks to genomic problems. Selected publications highlight interdisciplinary trends across genomics (e.g., Cis-regulatory landscapes , CTCF motif accessibility ) and computer science (e.g., Dynamic graph attention , Node classification ).

Tony Russellمشاهده پروفایل

دانشیار

• RNA Biology
• Evolutionary Biology
• Molecular Genetics
• +۵ مورد دیگر

Tony Russell is an Associate Professor in the Department of Biological Sciences at the University of Lethbridge. He earned his PhD in Biochemistry and Molecular Biology from the University of British Columbia and completed postdoctoral research at Dalhousie University, focusing on small RNA structure and evolution in unicellular eukaryotes. Education: PhD, University of British Columbia (Biochemistry and Molecular Biology) Postdoctoral Fellow, Dalhousie University The Russell lab investigates RNA biology and evolution through studies of small RNAs and protein-RNA complexes in protists. Key research areas include spliceosome evolution, intron dynamics, and genomic strategies to identify non-coding RNAs. Organisms under study include Euglena gracilis , Giardia lamblia , and Phytophthora species, with implications for understanding human diseases and pathogen biology. His publications in journals like Nature and RNA highlight discoveries such as ancient spliceosomal introns and novel snoRNA structures. The lab employs biochemical, structural, and bioinformatic approaches to unravel RNA functions and their evolutionary trajectories. Current research involves sequencing protist genomes to annotate small RNA genes and developing methods for identifying RNA modifications. The lab's work contributes to foundational knowledge in eukaryotic biology and potential applications in combating parasitic pathogens.

• Functional genomics
• tRNA biology
• Microbiome
• +۴ مورد دیگر

Professor Tao Pan is a leading researcher in RNA biology at the University of Chicago's Department of Biochemistry and Molecular Biology. His laboratory pioneers methodologies for studying tRNA dynamics, epitranscriptomics, and microbiome-host interactions through innovative sequencing technologies. His research spans three interconnected domains: tRNA biology : Developing high-throughput sequencing to measure tRNA abundance, charging, and modifications, revealing roles in translational control and extratranslational functions Microbiome characterization : Creating tRNA-seq as an RNA-based alternative to 16S/shotgun metagenomics to capture dynamic microbiome activity Epitranscriptomics : Investigating mRNA modifications like m6A in gene regulation, discovering the 'm6A switch' mechanism affecting RNA structure and protein binding His publication trends demonstrate consistent innovation in RNA modification mapping techniques, with recent work focusing on nanopore sequencing applications, microbiome-induced epitranscriptomic reprogramming, and therapeutic mRNA engineering. Key recurring themes include tRNA modification dynamics, host-microbiome crosstalk, and RNA modification detection methodologies. Scientific recognition includes: NIH Director's Pioneer Award (2011-2016) NIH EUREKA Award (2009-2013) AAAS Fellow (2015) Multiple early-career cancer research awards His laboratory maintains substantial NIH funding through multiple R01 grants (current awards totaling >$5M annually), focusing on tRNA sequencing applications in cancer (R33CA272357), microbiome-host interactions (R21AI169280), and snoRNA functions (R01HG012780). The Pan Lab has established tRNA-seq as a novel microbiome characterization platform and pioneered discoveries in m6A-mediated RNA structural switching. Research infrastructure includes development of specialized sequencing technologies for simultaneous tRNA modification and fragmentation analysis, with recent expansion into nanopore-based direct RNA modification detection. Current work explores therapeutic applications of tRNA modification knowledge in cancer and infectious disease contexts.